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FibrosisCardiac ﬁbrosis is marked by increased deposition of extracellular matrix components including ﬁbrillar col-
lagens, leading to impaired cardiac contractility and function. We recently demonstrated that the transcrip-
tion factor scleraxis is expressed in collagen-producing cardiac ﬁbroblasts and myoﬁbroblasts, is up-
regulated in the collagen-rich scar following myocardial infarction and is sufﬁcient to transactivate the
human collagen 1α2 (COL1A2) gene, suggesting a central role in ﬁbrosis. Here we describe the mechanism
of scleraxis-mediated regulation of the COL1A2 promoter. Using chromatin immunoprecipitation in primary
human cardiac ﬁbroblasts in combination with luciferase assays, we demonstrate that two E box sequences
within the proximal COL1A2 promoter are required for scleraxis-mediated transactivation. Expression of
scleraxis itself was induced by receptor Smad3, an effector of the pro-ﬁbrotic growth factor TGF-β1, and at-
tenuated by inhibitory Smad7. TGF-β1 augmented the effect of scleraxis on COL1A2 transactivation, an effect
which was due to synergy between scleraxis and Smad3. Mutation of the COL1A2 Smad-binding element sig-
niﬁcantly attenuated the ability of scleraxis to transactivate the promoter, while mutation of the scleraxis-
interacting E boxes attenuated the effect of Smad3, suggesting that these factors form a common signaling
complex at the promoter. COL1A2 promoter transactivation and Col1α2 gene expression in cardiac ﬁbro-
blasts were completely abrogated by a scleraxis basic domain deletion mutant in a dominant negative fash-
ion, blocking the ability of TGF-β1 to activate collagen synthesis and suggesting that scleraxis–DNA
interaction is absolutely required for this process. Scleraxis thus appears to play a key role in the transcrip-
tional regulation of type I collagen synthesis.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Cardiac ﬁbrosis is the relative increase in extracellular matrix (ECM)
synthesis that is a common pathological response to a wide variety of
stresses, including hypertension, valve disease, diabetes andmyocardial
infarction. Fibrosis interferes with both systolic and diastolic functions,
contributing to cardiac decompensation and failure, and increasing pa-
tient morbidity andmortality [1,2]. Treatments aimed speciﬁcally at re-
ducing ﬁbrosis thus have the potential to ameliorate the progression of
failure, but success in this area has been limited. For example, targeting
of the pro-ﬁbrotic TGF-β pathway has failed to yield a tractable anti-
ﬁbrotic therapy, despite the central role of this pathway in drivingﬁbro-
sis [3].
A key component of the ECM is type I collagen, representing over 40%
of the ﬁbrillar collagen present in both healthy and diseased hearts [4]., extracellular matrix; EMSA,
e real-time polymerase chain
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l rights reserved.Type I collagen is generated from two strands of procollagen 1α1 and
one strand of 1α2, which are secreted from cardiac ﬁbroblasts and
myoﬁbroblasts and undergo further processing in the extracellular mi-
lieu. Transcriptional regulation of procollagenmRNAsynthesis represents
a key point of control for managing matrix generation and ﬁbrosis. A pri-
mary regulator of this process is TGF-β, which acts via a heterodimeric
membrane-bound receptor to activate the Smad intracellular signaling
pathway. Following receptor-mediated phosphorylation, Smads migrate
to the nucleus and directly transactivate ECM genes such as collagen
1α2 [5,6]. Other transcriptional regulators including Sp1 and Sp3 also
contribute to collagen gene activity, and it is likely that still other players
are involved [7,8].
We recently demonstrated that the basic helix–loop–helix (bHLH)
transcription factor scleraxis was sufﬁcient to up-regulate expression
of the collagen 1α2 gene in primary cardiac ﬁbroblasts [9]. Scleraxis ex-
pression increased in cardiac myoﬁbroblasts – activated forms of ﬁbro-
blasts that synthesize elevated levels of collagen – or in response to
TGF-β1 treatment. Scleraxis expression was also elevated in the
collagen-rich scar following infarction. Others have reported that
scleraxis regulates expression of the collagen 1α1 gene in tenocytes,
and scleraxis gene deletion results in defects in the development of
intermuscular and force-transmitting tendons concomitant with type I
Table 1
ChIP assay PCR primers.
Primer Direction Sequence (5′→3′)
E boxes 1 & 2 Forward CTTCCCTCCCTCCTTCTCTG
Reverse ACTATGGGACACGTCGGAGT
E box 3 Forward CAAAAGTGTCCACGTCCTCA
Reverse CCCGGATCTGCCCTATTTAT
GAPDH Forward TACTAGCGGTTTTACGGGCG
Reverse TCGAACAGGAGGAGCAGAGAGCGA
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that scleraxis is a critical regulator of collagen gene expression in the
heart, either independently or downstream of TGF-β1. In the current
study, we found that scleraxis expression was up-regulated following
over-expression of pro-ﬁbrotic Smad3, and was down-regulated in re-
sponse to over-expression of inhibitory Smad7.
bHLH transcription factors including scleraxis regulate gene expres-
sion via interaction with deﬁned E box sequences (CANNTG, where N is
any nucleotide) [12,13]. We previously showed that scleraxis regulates
transactivation of the 3.7 kb human collagen 1α2 (COL1A2) gene pro-
moter [9]. Deletion of the scleraxis DNA-binding domain (ScxΔBD) at-
tenuated this transactivation, indicating that scleraxis must physically
contact the promoter. Here we report the identiﬁcation of two critical
E boxes within the COL1A2 proximal promoter that are required for
scleraxis-mediated promoter transactivation, determined by luciferase
assay and chromatin immunoprecipitation (ChIP).
These E boxes proximally ﬂank a Smadbinding element (SBE) previ-
ously shown to be critical for TGF-β induction of COL1A2 expression,
suggesting the possibility of co-regulation [14]. Using luciferase report-
er assays, we found that Smad3 synergistically up-regulated COL1A2
expression with scleraxis, while Smad7 was inhibitory and Smad2 had
a modest effect. Mutation of the SBE attenuated scleraxis-mediated
transactivation of the COL1A2 promoter, while mutation of the two E
boxes attenuated the effect of Smad3, suggesting that cooperation be-
tween these factors is required to support full promoter activation.
Because theDNA-binding domain of scleraxiswas absolutely required
for activity, we hypothesized that the DNA-binding mutant ScxΔBDmay
inhibit collagen 1α2 expression in a dominant negative fashion [9]. Lucif-
erase assays demonstrated that this mutant does, in fact, attenuate the
ability of intact scleraxis to regulate COL1A2 transactivation.More impor-
tantly, ScxΔBD inhibited collagen 1α2 expression in both NIH-3T3
ﬁbroblasts and primary rat cardiac myoﬁbroblasts, and made them
resistant to TGF-β1-mediated collagen up-regulation. Our results indicate
that scleraxis and Smads downstream of TGF-β1 work together to medi-
ate type I collagen expression, and suggest that interference with
scleraxis function may provide a new approach to the development of
anti-ﬁbrotic therapies.
2. Materials and methods
2.1. Cell culture
NIH-3T3 mouse embryonic ﬁbroblasts were cultured in DMEM
supplemented with 10% FBS, 1% penicillin/streptomycin and 1%
L-glutamine, and were seeded 24 h prior to transfection in 6-well cul-
ture plates to reach ~70% conﬂuence. Adult human cardiac ﬁbroblasts
were obtained commercially (Cell Applications Inc., USA). Primary
cardiac ﬁbroblasts were isolated from adult rats by Langendorff perfu-
sion of 0.1% collagenase type II (Worthington Biochemicals, USA).
Cells were collected after gentle centrifugation as previously described
[15] and maintained in DMEM-F12 supplemented with 10% FBS, 1%
penicillin/streptomycin and 1 mM L-ascorbic acid. Preparations ofﬁbro-
blasts obtained through thismethod are typically≥95% as conﬁrmed by
cell-speciﬁc marker analysis [16]. Animals were cared for in accordance
with the guidelines of the Canadian Council on Animal Care and the
University of Manitoba Animal Protocol Management and Review
Committee.
2.2. Chromatin immunoprecipitation assay (ChIP)
Adult human cardiac ﬁbroblasts (~8×106 cells) were grown in
100 mm dishes and ﬁxed by addition of 280 μl 37% formaldehyde to
10 ml of culture media for 10 min at 37 °C. The cells were then washed
with ice-cold PBS and harvested in SDS lysis buffer. Cell lysates were
sonicated to shear DNA to 200–500 bp fragments. A 1% aliquot of this
cell lysate was used as an input control. Samples were pre-clearedwith 75 μl bovine serum albumin (0.5 mg/ml)/herring sperm DNA
(200 μg/ml)/protein A-agarose mixture for 1 hour with rotation at
4 °C to reduce non-speciﬁc background. Lysates with soluble chromatin
collected after brief centrifugation were incubated at 4 °C overnight
with 10 μg anti-scleraxis antibody or 10 μg pre-immune serum as a
negative control. The production of this antibody by our laboratory
was previously described [9]. The DNA-protein immune complexes
were precipitated, washed, eluted and subsequently reverse cross-
linked, then puriﬁed by phenol/chloroform extraction. DNA samples
were subjected to PCR ampliﬁcation using primers speciﬁc to the
scleraxis-binding E box sequences (Table 1) in the human COL1A2
gene proximal promoter. Primers encompassing a region of the human
GAPDH promoter were used as a negative control (Table 1; Upstate
Cell Signaling Solutions EZ ChIP kit).
2.3. Luciferase reporter assays
NIH-3T3 ﬁbroblasts were seeded in 6-well dishes 24 h prior to
transfection to reach ~80% conﬂuency. Samples were co-transfected
(Lipofectamine 2000; Invitrogen, USA) with 500 ng reporter plasmid
(COL1A2 full-length 3.7 kb or 0.7 kb proximal promoters, or empty
pGL3 Basic as a control) plus 500 ng expression vectors as needed
(pECE-HA-FLAG-Scx, pECE-ScxΔBD, pCMV tag3C-Myc-Smad3, pCMV
tag3C-Myc-Smad2, pcDNA3.1(+)-FLAG-Smad7). Mutation of the E
boxes and SBE within the COL1A2 0.7 kb promoter was performed
using a QuikChange II Site-Directed Mutagenesis kit (Stratagene) and
nested PCR using primers listed in Table 2. Renilla luciferase expression
vector (pRL)was used as a transfection control. The luciferase activity of
each sample was assayed using the Dual Luciferase Reporter Assay Sys-
tem (Promega, USA) on a TD20/20 luminometer (Turner BioSystems,
USA).
2.4. Treatment of cells
NIH-3T3 ﬁbroblasts were grown to ~70% conﬂuency, then co-
transfected with COL1A2 0.7 kb reporter plasmid and pECE-HA-FLAG-
Scx expression vector for luciferase assays, or with pECE-HA-FLAG-Scx
or pECE-ScxΔBD expression vectors alone for mRNA analysis. Cells
were treated with 10 ng/ml TGF-β1 or vehicle for 24 h post-
transfection where required. Cell lysates were collected for luciferase
assay or qRT-PCR. Primary rat cardiac myoﬁbroblasts (passage 2)
were grown in 6-well tissue culture dishes to ~70% conﬂuence in com-
pletemedium followed by equilibration for 24 h in serum-freemedium.
Cells were infected with adenoviruses encoding LacZ (AdLacZ), FLAG-
Smad3 (AdSmad3), FLAG-Smad7 (AdSmad7), FLAG-scleraxis, FLAG-
ScxΔBD or LacZ (control) for 24 h. Serum-free medium was replaced
and cells were then treated with 10 ng/ml TGF-β1 or vehicle as re-
quired, and were harvested for protein or RNA 24 h later. Total protein
and total RNA was used for western blotting and qPCR analysis respec-
tively. The scleraxis adenovirus was described previously [9]. To gener-
ate the ScxΔBD adenovirus, we used PCR to amplify and sub-clone the
ScxΔBD coding region into pSHUTTLE-CMV transfer vector from the
AdEasy Vector System (Qbiogene, Canada). The shuttle vector was
then cloned into BJ5183 bacterial cells to generate replication-
deﬁcient adenoviruses.
Table 2
COL1α2 proximal promoter cloning and mutagenesis PCR primers.
Primer Direction Sequence (5′→3′)
COL1α2—0.7 kb Forward GCCCTTTCCCGAAGTCATAAGAC
Reverse TCGAGCCCGGGCTAG
ΔE1 mutagenesis Forward GAGCCCTCCACCCTACCATGGGCCTACAGGGCACAG
Reverse CTGTGCCCTGTAGGCCCATGGTAGGGTGGAGGGCTC
ΔE2 mutagenesis Forward GGCCTACAGGGCACTGCAGAGGCGGGACTGGA
Reverse TCCAGTCCCGCCTCTGCAGTGCCCTGTAGGCC
ΔE3 mutagenesis Forward CGCAGGCTCCTCCCCCGGGTGGCTGCCCGGGC
Reverse GCCCGGGCAGCCACCCGGGGGAGGAGCCTGCG
ΔSBE mutagenesis Forward ATGCGGAGGGCGGAGGTATGCGCACAACGAGTCAGAGTTTCCCCTT
Reverse AAGGGGAAACTCTGACTCGTTGTGCGCATACCTCCGCCCTCCGCAT
Underlined sequences denote mutated E boxes or SBE in the COL1A2 proximal promoter.
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Total RNA was isolated from cells using commercial kits (Sigma,
USA) according to manufacturer's instructions. 25 ng RNA was used
for each of the reactions performed using the qScript One-Step SYBR
Green qRT-PCR Kit for iQ (Quanta Biosciences, USA) on an iQ5
multicolor real-time PCR thermocycler (Bio-Rad, USA). mRNA abun-
dance was calculated using the 2−ΔΔCT method and was normalized
to GAPDH. Speciﬁc primers used to amplify sequences of interest are
listed in Table 3.
2.6. Western blotting
Total cell proteinwas isolated using RIPA buffer (50 mMTris pH 7.4,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% Na-deoxycholate, 1%
Triton-X 100 and 0.1% SDS) containing completemini protease inhibitor
cocktail (Roche, Canada). Proteins were separated by SDS-PAGE and
then transferred to PVDF membranes (Pall, USA). Primary antibodies
used for western blotting were rabbit anti-scleraxis antibody [9],
mouse anti-α-tubulin antibody (DSHB, USA) or rat anti-collagen type
I antibody (Cedarlane, Canada). Antibodies were detected using West-
ern Blotting Luminol Reagent (Santa Cruz Biotechnology, USA) and
CL-Xposure blue X-ray ﬁlm (Thermo Scientiﬁc, Canada). Quantity One
software (Bio-Rad, USA) was used to measure relative band intensity.
The intensity of the scleraxis bands was normalized to those of
α-tubulin to control for loading.
2.7. Electrophoretic mobility shift assay (EMSA)
COS7 cells were transfected with 1 μg scleraxis expression vector,
and 48 h later nuclear proteins were isolated using NE-PER nuclear and
cytoplasmic extraction reagents (Pierce Biotechnology, USA). 5 μl nucle-
ar extract was used in binding reactions as required. Assays were
performed using a Lightshift Chemiluminescent EMSA kit (Pierce Bio-
technology, USA) as per manufacturer's instructions. Binding reactions
were incubated at room temperature for 30 min in buffer containing
10 mM Tris pH 7.5, 100 mM KCl, 0.5 mM EDTA, 5% glycerol, 50 ng
poly(dI-dC), 5 μg bovine serum albumin and 20 fmol biotin end-
labeled probe. For competition experiments, a 250-fold molar excess
(5 pmol) of unlabeled probe was included in the binding reactions and
incubated for 15 min before addition of the labeled probes. For supershiftTable 3
qRT-PCR primers [9].
Amplicon Direction Sequence (5′→3′)
Scleraxis Forward AACACGGCCTTCACTGCGCTG
Reverse CAGTAGCACGTTGCCCAGGTG
Col1α2 Forward GTCCCCGAGGCAGAGAT
Reverse CCTTTGTCAGAATACTGAGCAGC
GAPDH Forward TGCACCACCAACTGCTTAGC
Reverse GGCATGGACTGTGGTCATGAGreactions, 1 μg anti-scleraxis antibody was incubated overnight at 4 °C
prior to addition of the biotin-labeled probes to the reaction [9].
DNA-protein complexes were then fractionated on a non-denaturing
6% native polyacrylamide gel at 100 V for 1 h. Chemiluminescent com-
plexes were detected using CL-XPosure clear blue ﬁlm (Thermo Scientif-
ic, Canada).
2.8. Statistical analysis
Statistical signiﬁcance of data was determined using Student t-test
or one-way analysis of variance (ANOVA) with Student-Newman–
Keuls post-hoc analysis. Results with pb0.05 were considered statisti-
cally signiﬁcant.
3. Results
3.1. Regulation of scleraxis expression by Smads
We previously reported that scleraxis expression is up-regulated in
cardiacﬁbroblasts by TGF-β1, and in turn regulates the COL1A2 promot-
er [9]. Because Smads are the primary mediator of TGF-β1 signals in ﬁ-
brosis, we assayed the effect of pro-ﬁbrotic Smad3 or inhibitory
Smad7 on scleraxis expression. Adenoviruses encoding Smad3 or
Smad7 were used to transfect primary rat cardiac ﬁbroblasts. Smad3
over-expression signiﬁcantly up-regulated scleraxis expression, while
Smad7 attenuated scleraxis expression (Fig. 1). These changes were ob-
served at the level of both transcription and translation, and demon-
strate that Smad signaling can regulate scleraxis expression.
3.2. Scleraxis transactivation of the proximal COL1α2 gene promoter
Scleraxis binds speciﬁcally to E boxes similar to other bHLH tran-
scription factors [12,17]. We previously noted the existence of up to
12 putative E boxes in the human 3.7 kb COL1A2 gene promoter [9].
Three of these sites are located within the proximal COL1A2 gene pro-
moter (~700 bp), a region that is highly responsive to TGF-β1 signaling
and rich in binding sites for transcription factors that regulate collagen
synthesis including Sp1, Sp3 and Smads [7,8]. To testwhether this prox-
imal region could be transactivated by scleraxis, we ampliﬁed by
high-ﬁdelity PCR a sequence comprising 706 bp of the COL1A2 proxi-
mal promoter, including 54 bp of 5′ untranslated region. This sequence
was sub-cloned into the luciferase reporter vector pGL3 Basic for further
study. This sequence encompasses three putative E boxes, in contrast to
previously-reported COL1A2 proximal promoter constructs which lack
the two most 5′ distal E boxes [18].
We examined the relative transactivation by scleraxis of the proxi-
mal COL1A2 promoter (COL1A2pr-0.7) compared to the full-length
3.7 kb promoter (COL1A2pr-3.7). Both promoters were strongly and
signiﬁcantly transactivated by scleraxis, but the proximal promoter
exhibited a nearly three-fold higher level of activity compared to the
full-length promoter (Fig. 2A). We also compared transactivation of
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Fig. 1. Regulation of scleraxis expression by Smads. A) Primary adult rat cardiac ﬁbro-
blasts were infected with adenovirus encoding Smad3 (MOI10), Smad7 (MOI100) or
LacZ (MOI10 or 100) adenoviruses. After treatment for 24 h, cells were lysed and
total RNA was isolated for quantitative PCR. Scleraxis mRNA abundance was calculated
using the 2−ΔΔCT method and normalized to GAPDH. Results represent three indepen-
dent experiments, normalized to AdLacZ (control), and are reported as mean±stan-
dard error; *pb0.05 vs. AdLacZ. B) Isolated adult rat cardiac ﬁbroblasts were infected
with adenoviruses encoding LacZ or Smads as in A. Twenty-four hours later, total cell
protein was isolated for western blotting with anti-scleraxis antibodies and
α-tubulin as a loading control. Numbers refer to molecular weight in kilodaltons. Re-
sults are quantiﬁed in C and represent three independent experiments, normalized to
α-tubulin expression, and are reported as mean±standard error; *pb0.05 vs. AdLacZ.
A
B
pGL3 COL1 2pr-3.7 COL1 2pr-0.7
0
20
40
60
80
100
120
140
160
180
Lu
ci
fe
ra
se
 e
xp
re
ss
io
n 
(fo
ld)
*
*
#
0
2
4
6
8
Lu
ci
fe
ra
se
 e
xp
re
ss
io
n 
(fo
ld)
Empty vector
Scleraxis
*
*
#
COL1 2pr-3.7 COL1 2pr-0.7
Fig. 2. Transactivation of the proximal human COL1A2 promoter by scleraxis. A) NIH-
3T3 ﬁbroblasts at ~70% conﬂuence were co-transfected with luciferase reporter plas-
mids (3.7 kb full length or 0.7 kb proximal COL1A2 promoter cloned into pGL3 Basic,
or empty pGL3 Basic (pGL3) as control) plus scleraxis expression vector (pECE-HA-
FLAG-Scx). Renilla luciferase expression vector pRL was co-transfected as a transfection
control. The luciferase activity of each sample was assayed 24 h later. Results of three
independent experiments were normalized to pGL3 and pRL, and are reported as
mean±standard error; *pb0.05 vs. pGL3, #pb0.05 vs. full length promoter. B) Lucifer-
ase reporter assays were performed as in A with either full length or proximal COL1A2
luciferase reporter vectors, plus empty pECE or scleraxis expression vector. Results
were normalized to pECE and pRL. Results of three independent experiments are
reported as mean±standard error; *pb0.05 vs. empty vector, #pb0.05 vs. full-length
promoter.
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empty expression vector. Again we observed that both promoters were
signiﬁcantly transactivated by scleraxis, and that the proximal promot-
er was induced to a statistically signiﬁcantly greater degree than the
full-length promoter, also by approximately three-fold (Fig. 2B). Theseresults suggest that the full-length promoter may contain repressor el-
ements that negatively affect transactivation. These results also suggest
that transactivation of the COL1A2 gene by scleraxis may be largely de-
termined by sequences within the proximal promoter.
3.3. E box-mediated transactivation of the COL1A2 proximal promoter by
scleraxis
As noted above, the COL1A2 proximal promoter contains three puta-
tive scleraxis-binding E boxes (designated E1 to E3; Fig. 3A), including
one sequence (E2) that exactly matches a previously-deﬁned scleraxis
binding site in the aggrecan gene promoter [19]. Homologous E boxes
are located in the mouse and rat Col1α2 promoters in positions closely
proximal to their locations in the human promoter (Fig. 3A). Chromatin
immunoprecipation assay conﬁrmed that scleraxis directly binds to the
promoter regions encompassing the E box sequences present within
the COL1A2 promoter in normal human cardiac ﬁbroblasts ex vivo
(Fig. 3B). However, ChIP resolution is determined by the size of the
immunoprecipitated DNA fragments, typically 200 to 500 bp. The gap
between E1 and E2 is only 12 bp, while E1 and E3 are separated by
310 bp, thus while it is clear that scleraxis binds to this region, it is
1940 R.A. Bagchi, M.P. Czubryt / Biochimica et Biophysica Acta 1823 (2012) 1936–1944difﬁcult to ascertain by ChIP the importance of any single E box. To
determine which of these three sites are involved in scleraxis-
mediated transactivation of the COL1A2promoter, we performedmuta-
tion analysis studies in which individual or combinations of E boxes
were mutated to prevent scleraxis binding in luciferase reporter assays.
Mutation of any single E box (ΔE1,ΔE2 orΔE3; Fig. 3A) resulted in a sig-
niﬁcant attenuation of promoter transactivation by scleraxis, although
transactivation was still signiﬁcantly greater than control empty vectorA
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Rr(Fig. 3C). Intriguingly,mutation of both E1 and E3 completely prevented
promoter transactivation by scleraxis. Transactivation was signiﬁcantly
lower than control, and was signiﬁcantly decreased further when all
three E boxes (ΔE1/2/3) were mutated.
These results indicate that E boxes E1 and E3 are strictly required for
transactivation of the COL1A2 proximal promoter by scleraxis. Con-
versely, E2 appears to have a contributory effect but is not absolutely re-
quired: although E2 mutation alone reduced transactivation by
scleraxis, the double mutationsΔE1/2 and ΔE2/3 did not cause the dra-
matic attenuation observedwithΔE1/3, although the triple mutantwas
signiﬁcantly lower than ΔE1/3 (Fig. 3C). One possibility is that E2, sep-
arated from E1 by only 12 nucleotides, may indirectly modulate tran-
scription factor binding to E1, perhaps by affecting local DNA
topography and thus access by scleraxis to E1.
The attenuation of scleraxis-mediated transactivation of the COL1A2
promoter below control in the ΔE1/3 and ΔE1/2/3 experiments may be
due to endogenous scleraxis expression in the NIH-3T3 ﬁbroblasts used
in the reporter assay [9]. Thus, the intact COL1A2-pr0.7 promoter re-
porter may exhibit some activity even in the absence of exogenously-
added scleraxis. Mutation of the reporter E boxes would eliminate
transactivation by endogenous scleraxis, resulting in reporter activity
below control levels.
To conﬁrm the ability of scleraxis to bind to E boxes 1 and 3, electro-
phoreticmobility shift assayswere performed using scleraxis-containing
nuclear extracts and biotin-labeled oligonucleotides corresponding to
one or the other E box. A shifted band was observed for both E boxes
whichwas lost with a 250-fold excess of unlabeled oligonucleotide com-
petitor (Fig. 3D, arrows). Both bandswere supershifted upon inclusion of
anti-scleraxis antibody (Fig. 3D, arrowheads), conﬁrming the formation
of a scleraxis-DNA complex.3.4. Synergistic regulation of the COL1A2 promoter by scleraxis and
Smads
Multiple pro-ﬁbrotic TGF-β1-responsive signaling pathways con-
verge on the COL1A2 proximal promoter [7,8]. While we have shown
that TGF-β1 also induces scleraxis expression, and that scleraxis in
turn up-regulates COL1A2 expression, it is unclear whether TGF-β1
and scleraxis exert independent effects on promoter activation [9].
We therefore examinedwhether TGF-β1 and scleraxis exert additive ef-
fects on proximal COL1A2 promoter transactivation. While scleraxis
alone strongly activated the promoter, the addition of TGF-β1 inducedFig. 3. Interaction of scleraxis with the proximal COL1A2 promoter. A) The proximal
human COL1A2 gene promoter, spanning a region from −652 to +54 relative to the
transcription start site, contains three putative E boxes (black rectangles, denoted E1
to E3) that match the consensus CANNTG E box sequence. For comparison, the locations
of homologous E boxeswithin themouse (Mm) and rat (Rr) Col1α2 gene promoters are
depicted in comparison to the human (Hs) promoter. Binding sites for various other
regulatory transcription factors within the human promoter are indicated, including
Sp1 GC boxes (light gray ovals), Sp1/Sp3 T boxes (dark gray ovals), and a Smad Binding
Element (SBE; white rectangle). The E box and SBE mutations used in the study are also
indicated. B) Chromatin immunoprecipitation was performed on human cardiac ﬁbro-
blasts using anti-scleraxis (Scx) antibody or pre-immune serum. PCR primers were
used to amplify the collagen 1α2 promoter sequence ﬂanking E boxes 1 and 2 (E1/
E2) or E box 3 (E3). Genomic DNA was used as a positive input control. Scleraxis
binds to both the E1/E2 and E3 sites. A region of the human GAPDH promoter was
used as a negative control. C) Point mutations were sequentially introduced to the
three E boxes of the COL1A2 proximal promoter individually or in combination as per
the sequences shown in panel A. NIH-3T3 ﬁbroblasts were transfected with intact
(pr-0.7) or mutated (ΔE1, ΔE2 etc.) proximal COL1A2 promoter reporters plus
scleraxis expression vector or empty pECE (Control). pRL was co-transfected as a trans-
fection control. Twenty-four hours after transfection, luciferase assays were performed.
Results of three independent experiments were normalized to Control and pRL, and are
reported as mean±standard error; *pb0.001 vs. Control, #pb0.001 vs. pr-0.7. D) The
binding of scleraxis to E boxes 1 and 3 was conﬁrmed by EMSA. Scleraxis-containing
COS7 nuclear extracts were incubated with biotin-labeled oligonucleotide probes
corresponding to either E box. A 250-fold molar excess of unlabeled oligonucleotide
(250× cold) was used to compete the scleraxis-DNA complex (arrow). Inclusion of an
anti-scleraxis antibody resulted in a supershift of the complex (arrowhead).
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(Fig. 4A). This result suggests that scleraxis may function together
with other TGF-β1-responsive signaling pathways such as Smads.
To determine whether scleraxis directly interacts with the Smad
signaling pathway to regulate transcription, luciferase assays were
performed with scleraxis in combination with pro-ﬁbrotic Smad3,
Smad2 or inhibitory Smad7. As expected, either scleraxis or Smad3
alone signiﬁcantly transactivated the proximal COL1A2 promoter.
Smad2 alone had a statistically signiﬁcant but much more modest ef-
fect on COL1A2 transactivation. Intriguingly, scleraxis and Smad3
together exhibited synergistic activation of the promoter (~33-fold
activation, compared to 10~14-fold activation for scleraxis or
Smad3 alone; Fig. 4B). Conversely, Smad7 completely abrogated pro-
moter transactivation by scleraxis. Smad2 had no effect in combina-
tion with scleraxis, and only a modest effect when transfected with
Smad3 and scleraxis together, in keeping with its greatly diminished
ability to regulate gene expression compared to Smad3 [20].
3.5. Cross-talk in proximal COL1A2 promoter activation by Smad3 and
scleraxis
The scleraxis binding sites are in close juxtaposition with those of
other ﬁbrotic regulators: E1 and E3 are a mere 167 and 136 nucleotides,
respectively, away from the SBE (Fig. 3A), suggesting the possibility
that these sites contribute to the assembly of a common transcription
complex. We tested whether scleraxis-mediated transactivation of the
proximal COL1A2 promoter is dependent on Smad3 and vice versa.
Scleraxis-mediated promoter transactivation was signiﬁcantly attenuat-
ed bymutation of the SBE (Fig. 4C). Similarly, Smad3-mediatedpromoter
activation was signiﬁcantly attenuated by mutation of the two critical
scleraxis binding sites, E1 and E3 (Fig. 4D). In both cases, promoter
transactivation was reduced by approximately 50%, similar to the loss
of activity observed when the HLH protein–protein interaction domain
of scleraxis is deleted [9]. Collectively, these results suggest that scleraxis
and Smad3 functionally interact to regulate COL1A2 trans-activation.
3.6. Blockade of COL1A2 expression by a scleraxis dominant negative
mutant
bHLH transcription factors contain a basic domain that mediates
DNA binding [12,13]. Deletion of this domain may give rise to a protein
that acts in a dominant negative fashion to inhibit gene expression. For
example, Inhibitor of Differentiation 2 is an HLH transcriptional repres-
sor that functions by binding to ubiquitous bHLH factors like E12 and
E47, thus preventing these factors from forming heterodimers withFig. 4. Cross-talk between scleraxis and Smad signaling. A) NIH-3T3 ﬁbroblasts were
transfected with empty pECE (Control) or scleraxis expression vectors plus the proximal
COL1A2 luciferase reporter vector. Twenty-four hours later, cells were treated with vehicle
or 10 ng/ml TGF-β1 as indicated for an additional 24 h prior to luciferase assay. pRL was
co-transfected as a transfection control. Results of three independent experiments were
normalized to Control and pRL, and are reported as mean±standard error; *pb0.05 vs.
Control, #pb0.05 vs. scleraxis plus vehicle. B) Luciferase reporter assays were performed
using proximal COL1A2 promoter reporter vector, plus empty pECE or scleraxis expression
vector; or pCMV tag3C or pCMV tag3C-Myc-Smad3 or pCMV tag3C-Myc-Smad2; or
pcDNA3.1(+) or pcDNA3.1(+)-FLAG-Smad7. pRLwas co-transfected as a transfection con-
trol. Results of three independent experiments were normalized to the respective empty
vectors and pRL, and are reported as mean±standard error; *pb0.001 vs. empty vector,
#pb0.001 vs. scleraxis alone; &pb0.001 vs. Smad3 alone. C) NIH-3T3 ﬁbroblasts were
transfectedwith the intact (pr-0.7) or SBEmutant (pr-0.7ΔSBE) proximal COL1A2 promot-
er reporter or pGL3 (Control), plus scleraxis expression vector. pRL was co-transfected as a
transfection control. Twenty-four hours after transfection, luciferase assays were
performed. Results of three independent experimentswere normalized to empty pGL3 vec-
tor and pRL, and are reported as mean±standard error; *pb0.05 vs. pGL3, #pb0.05 vs.
pr-0.7. D) NIH-3 T3 ﬁbroblasts were transfected with the intact (pr-0.7) or double E box
mutant (pr-0.7ΔE1/3) proximal COL1A2 promoter reporter or pGL3 (Control), plus
scleraxis expression vector. pRL was co-transfected as a transfection control. Luciferase as-
says were performed 24 h after transfection. Results of three independent experiments
were normalized to empty pGL3 vector and pRL, and are reported as mean±standard
error; *pb0.05 vs. pGL3, #pb0.05 vs. pr-0.7.other bHLH proteins while at the same time interfering with binding
to DNA [21]. We previously generated a scleraxis mutant lacking the
DNA-binding basic domain (ScxΔBD) and demonstrated that this mu-
tant was completely unable to transactivate the COL1α2 promoter [9].pGL3 pr-0.7 pr-0.7ΔSBE
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tor of COL1α2 promoter transactivation via luciferase assays inNIH-3T3
ﬁbroblasts using ScxΔBD in combination with scleraxis. Scleraxis-
mediated transactivation of the proximal COL1A2 promoter was atten-
uated by ScxΔBD in a dose-dependent manner, with as little as 100 ng
transfected ScxΔBD vector sufﬁcient to completely block transactiva-
tion (Fig. 5A). The three highest doses of ScxΔBD vector signiﬁcantly re-
duced luciferase activity below the level of the empty vector control. As
in Fig. 3C above, this suggests that basal transactivation of the reporter
by endogenous factors was inhibited, and demonstrates that the
ScxΔBD mutant does, indeed, behave as a dominant negative regulator
of scleraxis-mediated gene transactivation.A
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Fig. 5. Inhibition of collagen 1α2 expression by a scleraxis dominant negative mutant
ScxΔBD. A) NIH-3T3 ﬁbroblasts were transfected with the proximal COL1A2
promoter reporter plus empty pECE (Control) or intact scleraxis expression vectors.
Some samples were co-transfected with increasing amounts (20, 100, 250 or 500 ng
DNA) of ScxΔBD. pRL was co-transfected as a transfection control. Twenty four hours
after transfection, luciferase assays were performed. Results of three independent ex-
periments were normalized to pECE and pRL, and are reported as mean±standard
error; *pb0.05 vs. Control, #pb0.05 vs. intact scleraxis alone (−). B) NIH-3T3
ﬁbroblasts were transfected with empty pECE, intact scleraxis or ScxΔBD expression
vectors. Twenty four hours later, cells were treated with vehicle or 10 ng/ml TGF-β1.
After another 24 h, total RNA was isolated for quantitative RT-PCR. Col1α2 mRNA
abundance was calculated using the 2−ΔΔCT method and was normalized to GAPDH.
Results of three independent experiments were normalized to samples receiving
empty vector plus vehicle, and are reported as mean±standard error; *pb0.05 vs.
empty vector+vehicle, #pb0.05 vs. corresponding intact scleraxis-transfected sam-
ples. NS, not signiﬁcant. C) A similar experiment was carried out as in panel B, using
primary rat passage 2 myoﬁbroblasts and adenoviruses encoding scleraxis or ScxΔBD
(MOI 10). Results of three independent experiments were normalized to samples re-
ceiving empty vector plus vehicle, and are reported as mean±standard error;
*pb0.01 vs. empty vector+vehicle, #pb0.001 vs. corresponding intact scleraxis-
infected samples; &pb0.01 vs. empty vector plus TGF‐β1. NS, not signiﬁcant. D) Prima-
ry rat passage 2 myoﬁbroblasts were treated with vehicle or 10 ng/ml TGF-β1 with or
without adenovirus encoding the ScxΔBD mutant for 24 h. Total protein lysates were
separated by SDS-PAGE, western blotted as in the Materials and methods and visual-
ized using anti-collagen type I antibody. α-tubulin was used as a loading control.We next examined whether ScxΔBD could interfere with TGF-
β1-mediated induction of collagen 1α2 gene expression. We con-
ﬁrmed that collagen 1α2 mRNA expression was up-regulated to sim-
ilar levels in NIH-3T3 ﬁbroblasts in response to TGF-β1 treatment or
scleraxis over-expression (Fig. 5B). Strikingly, ScxΔBD completely ab-
rogated that effect of TGF-β1 on collagen 1α2 expression in these
cells. Indeed, ScxΔBD also resulted in a signiﬁcant reduction in basal
collagen 1α2 mRNA expression compared to vehicle-treated cells
transfected with an empty expression vector. These results support
the suggestion that scleraxis plays a critical role in mediating
TGF-β1-induced COL1α2 gene expression, and demonstrate that
ScxΔBD is capable of interfering with TGF-β1-mediated collagen pro-
duction. We conﬁrmed these results in primary rat passage 2 cardiac
myoﬁbroblasts at both the mRNA and protein level (Fig. 5C, D).
4. Discussion
Cardiac ﬁbrosis remains a signiﬁcant health problem, with virtual-
ly no approved therapies directly targeting this process in human pa-
tients. In light of the contributory nature of ﬁbrosis in cardiac
diseases, the identiﬁcation of novel regulators of this pathological
process is thus an important goal for the development of new thera-
peutic approaches to improve patient outcomes. The data presented
here support our hypothesis that scleraxis is an important new target
for the development of these anti-ﬁbrotic therapies, and provides an
example of a novel approach to attenuating collagen 1α2 production
using our ScxΔBD mutant [3,9].
Hereinwe have clariﬁed themechanism bywhich scleraxis regulates
human COL1A2 gene expression by determining the relative importance
of three E boxes within the proximal gene promoter. Mutation analysis
reveals that E1 and E3 are critical for scleraxis-mediated transactivation
of this promoter (Fig. 3C). The ﬁnding that scleraxis binds to these E
boxes under basal conditions in adult human cardiac ﬁbroblasts
(Fig. 3B) suggests that scleraxis contributes directly to maintenance of
normal cardiac ﬁbroblast collagen expression. Pro-ﬁbrotic conditions in-
duce scleraxis expression, further augmenting collagen gene expression
as reported by our laboratory [9]. The potent increase in collagen gene
expressionmediated by scleraxis (Figs. 2–5), coupledwith the induction
of scleraxis expression by TGF-β1 [9] or its effector Smad3 (Fig. 1) indi-
cates that scleraxis represents a novel TGF-β1-inducible mechanism to
regulate collagen synthesis.
Until now, it has been unclear whether scleraxis represents a wholly
novel mechanism for regulating collagen expression independent of
1943R.A. Bagchi, M.P. Czubryt / Biochimica et Biophysica Acta 1823 (2012) 1936–1944existing pathways such as TGF-β1/Smad signaling. The data presented
here suggests that, while scleraxis alone is sufﬁcient to regulate collagen
1α2 expression, there is extensive cross-talk between scleraxis and
the TGF-β1/Smad signaling network. We found that scleraxis expression
was signiﬁcantly up-regulated in response to Smad3 but down-
regulated by inhibitory Smad7 in primary rat cardiac ﬁbroblasts
(Fig. 1). Thisﬁnding places scleraxis downstreamof TGF-β1/Smad signal-
ing, although it is likely that other independent signalsmay be capable of
inducing scleraxis expression.
Importantly, there appears to be considerable functional interaction
between scleraxis and Smad3. Analysis of the proximal COL1A2 gene
promoter reveals tight ﬂanking of the SBE by the E boxes that are critical
for scleraxis-mediated regulation (Fig. 3A), suggesting the possibility
that scleraxis and Smad3 form a common transcriptional complex. How-
ever, co-immunoprecipitation experiments failed to demonstrate an ac-
tual physical interaction between scleraxis and Smad3 (results not
shown). Smad2 does not appear to play a critical role in this regard,
and thus does not functionally substitute for Smad3: Smad2 exerted sta-
tistically signiﬁcant (pb0.01) but very modest effects on COL1A2 pro-
moter transactivation, either alone or in combination with scleraxis
and/or Smad3 (Fig. 4B). This is not surprising given a previous report
that Smad2 is a much weaker driver of TGF-β-mediated gene
transactivation than Smad3 [20].
Despite an apparent lack of physical interaction between Smad3 and
scleraxis, there is clear functional interaction between these factors,
since mutation of the SBE signiﬁcantly attenuated scleraxis-mediated
promoter transactivation, while mutation of the E boxes had the same
effect on Smad3 (Fig. 4C, D). In both cases, the promoter mutations
did not eliminate the ability of scleraxis or Smad3 to transactivate the
promoter, suggesting that either factor alone can drive transcription,
albeit with reduced activity. This ﬁnding thus conceptually agrees
with our previous study in which deletion of the scleraxis HLH protein–
protein interaction domain reduced but did not eliminate scleraxis
activity to a similar degree (~50%). We postulated at the time that HLH
deletion prevented scleraxis from interacting with a key co-factor or
partner, thus reducing but not eliminating its activity [9]. We hypothe-
sized that this partner may be Smad3, since scleraxis and Smad3
exhibited a synergistic effect on COL1A2 promoter activation compared
to either factor alone (Fig. 4B) and since previous studies have demon-
strated binding of Smads (including Smad3) to bHLH transcription
factors [22,23]. However, since our initial co-immunopreciptation ex-
periments appear to rule this interaction out, it is necessary to consider
the possibility that these factors may simply form part of a commonTGF- 1
Smad 3
Scleraxis
Smad7
Fig. 6. Proposed model for interaction of scleraxis and Smads in the regulation of COL1A2 ge
plex to activate Smad3, which in turn regulates the COL1A2 gene via direct binding to the
expression via an unknown mechanism. Both effects of Smad3 are negatively regulated by
strongly up-regulate COL1A2 expression via scleraxis binding to E boxes within the proximtranscriptional complex. It is also possible that these factors both bind
to a common but as yet unknown partner.
It is likely that scleraxis partners with other proteins for full activity.
While our dominant negative ScxΔBD DNA-binding mutant potently
blocked collagen 1α2 expression (Fig. 5), deletion of the SBE in the
COL1A2 promoter only reduced transactivation by scleraxis by ~50%
(Fig. 4C). If scleraxis was absolutely dependent on Smad3 for formation
of a transcription complex, one would expect complete attenuation of
scleraxis-mediated transactivation of the SBE mutant promoter. Others
have suggested that full scleraxis activity may be dependent on
heterodimerization with ubiquitous E box-binding proteins such as
E12 and E47 [11,12,17,19,24]. The very close spacing of the E boxes E1
and E2 within the COL1A2 promoter may facilitate interaction with
just such a heterodimer. This may explain why deletion of E2 reduced
activation of the promoter by scleraxis, but was not as critical as E1
and E3 (Fig. 3C): scleraxis could bind the promoter alone, without a
binding partner, but still maintain partial activity consistent with our
scleraxis HLH mutant. However, others have suggested that E protein
heterodimerization with scleraxis is not absolutely required for
scleraxis function and our own previous data indicates that E12 and
E47 are not regulators of scleraxis-mediated transactivation of the
COL1A2 promoter, thus the importance of these E proteins is likely to
be gene- or context-dependent [9,19].
While protein–protein interaction may not be required for scleraxis
function, our results suggest that scleraxis itself plays a critical role in
regulating collagen gene expression. ScxΔBD not only attenuated basal
collagen 1α2 mRNA expression, it also fully prevented induction by
TGF-β1, a potent inducer of ﬁbrosis (Fig. 5B–D). These ﬁndings, when
considered in the context of the report that scleraxis knockout results
in improper development of force-transmitting tendons lacking type I
collagen, strongly support a key central role for scleraxis in ﬁbrillar col-
lagen synthesis inmultiple tissues [10]. Our ScxΔBDmutant proteinmay
be useful for proof-of-concept experiments to demonstrate a central role
for scleraxis in ﬁbrosis. We have shown that scleraxis is up-regulated in
the collagen-rich cardiac infarct scar, and others have demonstrated that
scleraxis expression becomes activated in collagen-rich dermal keloids
[9,25]. Both of these disparate pathologies are regulated by TGF-β1,
thus it is possible that interferencewith scleraxis functionmay be a use-
ful approach in a number of ﬁbrotic diseasesmarked by over-expression
of type I collagen including cardiacﬁbrosis [26,27]. The results presented
here support a model of COL1A2 gene expression mediated by the syn-
ergistic interaction of scleraxis and Smad3 downstream of TGF-β1
(Fig. 6).COL1 2Scleraxis ScleraxisSmad 3
E1/2 E3SBE
ne expression. Pro-ﬁbrotic TGF-β1 binds to its plasma membrane-bound receptor com-
SBE located in the promoter. Our data demonstrates that Smad3 also induces scleraxis
inhibitory Smad7. Increased scleraxis expression works synergistically with Smad3 to
al promoter.
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